Immunome Inc Stock Price, News & Analysis

Immunome (Nasdaq: IMNM) announced promising results for its three-antibody cocktail, IMM-BCP-01, which showed potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical tests. The company received a $17.6 million award from the U.S. Department of Defense to support its COVID program. With concerns over potential COVID-19 resurging due to new variants, Immunome plans to expedite the development of IMM-BCP-01 and submit an IND application to the FDA this quarter, potentially positioning the drug as a long-term solution to COVID-19.

Immunome, a biopharmaceutical company focused on first-in-class antibody therapeutics, announced that its President and CEO, Purnanand Sarma, Ph.D., will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, at 10:30 a.m. ET. The presentation can be accessed via a live audio webcast on the company’s website, with a replay available for 30 days. Immunome leverages its human memory B cell discovery engine to develop therapies for oncology and infectious diseases, including COVID-19.

Immunome, Inc. (Nasdaq: IMNM) has appointed Andrew D. Badley, M.D., to its COVID-19 Advisory Board. Dr. Badley, Chair of the Mayo COVID-19 Research Taskforce, is recognized for his expertise in infectious diseases and will provide critical insights as Immunome develops antibody therapeutics for COVID-19 and other outbreaks. His extensive background includes significant roles at the Mayo Clinic and a focus on virus-host interactions, aiming to enhance therapeutic approaches in infectious diseases.

Immunome (Nasdaq: IMNM) has appointed Dr. Franklyn G. Prendergast to its Board of Directors, enhancing its leadership during a pivotal transition from preclinical to clinical stages. Dr. Prendergast, recognized for his extensive medical and academic experience, aims to contribute to the development of antibody therapeutics targeting diseases with unmet needs. Concurrently, Michael Widlitz, a long-serving director, will transition to an advisory role in Medical Affairs. This strategic management change is expected to leverage Immunome's innovative platform for therapeutic advancement.

Immunome, Inc. (Nasdaq: IMNM) has announced that Purnanand Sarma, Ph.D., President and CEO, will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 8:00 a.m. ET. Interested parties can access the live audio webcast through the Investor Relations section of the company's website, with a replay available for 30 days after the event. Immunome focuses on developing first-in-class antibody therapeutics using its human memory B cell discovery engine, targeting oncology and infectious diseases, including COVID-19.

Immunome, Inc. (Nasdaq: IMNM) announced a $4.3 million funding increase from the U.S. Department of Defense, raising total support to $17.6 million for its antibody cocktail, IMM-BCP-01, aimed at combating SARS-CoV-2. This additional capital will facilitate the expansion of clinical studies following FDA feedback. The antibody cocktail, comprising three monoclonal antibodies, targets multiple SARS-CoV-2 variants with high affinity. Immunome is working towards an IND filing for IMM-BCP-01 in late 2Q/early 3Q 2021.

Immunome, a biopharmaceutical company focused on antibody therapeutics, reported its Q1 2021 financial results, revealing a net loss of $3.9 million and R&D expenses of $2.0 million. The company announced significant advancements, including the discovery of antibodies neutralizing SARS-CoV-2 variants and plans for an IND filing for the IMM-BCP-001 cocktail in late Q2 or early Q3 2021. Additionally, Immunome appointed Dr. Dennis Giesing as Chief Development Officer and Corleen Roche as Chief Financial Officer. A $27 million private placement is expected to fund operations through 2022.

Immunome, Inc. (Nasdaq: IMNM) announced antibody selection for its IMM-BCP-01 cocktail, showing effectiveness against SARS-CoV-2 variants in preclinical tests. The cocktail, comprising three monoclonal antibodies, demonstrated full neutralization against several variants, including those resistant to current therapeutics. The company plans to file an IND for IMM-BCP-01 in late Q2/early Q3 2021, supported by a $13.3 million agreement with the U.S. Department of Defense. Immunome aims to pioneer treatments for oncology and infectious diseases through its patient memory B cell platform.

Immunome (Nasdaq: IMNM) has entered into a definitive securities purchase agreement to sell its equity securities in a private placement, securing approximately $27 million in gross proceeds. The deal involves the sale of 1,000,000 units at $27.00 per unit, each comprising one share of common stock and a warrant for an additional half share at $45.00 per share. Funds will support the development of its oncology and infectious disease portfolio, including COVID-19. The transaction is expected to close on April 28, 2021, pending customary conditions.